Synthesis and biological evaluation of new clofibrate analogues as potential PPARα agonists

European Journal of Medicinal Chemistry

Volumn 40, Issue 2, 2005, Pages 143-154

  Perrone, Maria Grazia ^a   Santandrea, Ernesto ^a   Dell'Uomo, Natalina ^b   Giannessi, Fabio ^b   Milazzo, Ferdinando Maria ^b   Sciarroni, Anna Floriana ^b   Scilimati, Antonio ^a   Tortorella, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Ricerca e Sviluppo   (Italy)

Author keywords

Clofibrate analogues; Dyslipidemia; Ethyl 2 (4 chlorophenoxy) 3 oxoalkanoates; Ethyl 2 (4 chlorophenoxy) 3 hydroxyalkanoates

Indexed keywords

2 (4 CHLOROPHENOXY) 3 HYDROXY 2 METHYLBUTANOIC ACID; 2 (4 CHLOROPHENOXY) 3 HYDROXY 3 PHENYLPROPANOIC ACID; 2 (4 CHLOROPHENOXY) 3 HYDROXY 4 METHYLPENTANOIC ACID; 2 (4 CHLOROPHENOXY) 3 HYDROXYBUTANOIC ACID; 2 (4 CHLOROPHENOXY) 3 HYDROXYHEXANOIC ACID; 2 (4 CHLOROPHENOXY) 3 HYDROXYPENTANOIC ACID; 2 (4 CHLOROPHENOXY) 4,4 DIMETHYL 3 HYDROXYPENTANOIC ACID; ALKANE DERIVATIVE; CHLORINE DERIVATIVE; CHLOROPHENOL; CLOFIBRATE; ETHYL 2 (4 CHLOROPHENOXY) 3 HYDROXY 3 PHENYLPROPANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 HYDROXY 4 METHYLPENTANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 HYDROXY 4,4 DIMETHYLPENTANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 HYDROXYBUTANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 HYDROXYHEXANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 HYDROXYPENTANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 OXO 3 PHENYLPROPANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 OXO 4 METHYLPENTANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 OXO 4,4 DIMETHYLPENTANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 OXOBUTANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 OXOHEXANOATE; ETHYL 2 (4 CHLOROPHENOXY) 3 OXOPENTANOATE; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRINIXIC ACID; SODIUM; SODIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CHEMICAL REACTION; COMMERCIAL PHENOMENA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; FIBROBLAST; MONKEY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY;

ANIMALS; ANTILIPEMIC AGENTS; CELL LINE; CLOFIBRATE; ESTERS; FIBROBLASTS; HAPLORHINI; KIDNEY; MODELS, CHEMICAL; PPAR ALPHA; STEREOISOMERISM; TRANSCRIPTION FACTORS;

EID: 13444266178     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmech.2004.09.018     Document Type: Article

References (24)

1. J. Berger, and D.E. Moller Annu. Rev. Med. 53 2002 409 435
2. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.C. Fruchart Circulation 98 1998 2088 2093
3. C. Sgro, and A. Escousse Therapie 46 1991 351 354
4. P. Gariot, E. Barrat, L. Mejean, J. Pointel, P. Drouin, and G. Debry Arch. Toxicol. 53 1983 151 163
5. B. Angelin, K. Einarsson, and B. Leijd Eur. J. Clin. Invest. 14 1984 73 78
6. M. Evans, and A. Rees Drug Safety 25 2002 649 663
7. D. Conte-Camerino, V. Tortorella, E. Ferrannini, and S.H. Bryant Arch. Toxicol. 7 1984 482 484
8. M. Tikkanen Curr. Opin. Lipidol. 3 1992 29 33
9. P. Zimetbaum, W. Frishman, and S.J. Kahn Clin. Pharmacol. 31 1991 25 37
10. D.R. Feller, V.S. Kamanna, H.A.I. Newman, K.J. Romstedt, D.T. Witiak, G. Bettoni, S.H. Bryant, D. Conte-Camerino, F. Loiodice, and V. Tortorella J. Med. Chem. 30 1987 1265 1267
11. G. Bettoni, F. Loiodice, V. Tortorella, D. Conte-Camerino, M. Mambrini, E. Ferrannini, and S.H. Bryant J. Med. Chem. 30 1987 1267 1270
12. T.A. Esbenshade, V.S. Kamanna, H.A.I. Newman, V. Tortorella, D.T. Witiak, and D.R. Feller Biochem. Pharmacol. 40 1990 1263 1274
13. N. Inomata, H. Yoshida, Y. Aoki, M. Tsunoda, M. Yamamoto, and J. Tohoku Exp. Med. 165 1991 171 182
14. E. Ciolek, and M. Dauca Biol. Cell. 71 1991 313 320
15. S. Ferorelli, C. Franchini, F. Loiodice, M.G. Perrone, A. Scilimati, M.G. Sinicropi, and P. Tortorella Tetrahedron: Asymmetry 12 2001 853 862 (and references cited therein)
16. S. Ferorelli, F. Loiodice, V. Tortorella, R. Amoroso, G. Bettoni, D. Conte-Camerino, and A. De Luca Farmaco 52 1997 367 374 (and references cited therein)
17. S.M. Rangwala, M.L. O'Brien, V. Tortorella, A. Longo, F. Loiodice, D.J. Noonan, and D.R. Feller Chirality 9 1997 37 47
18. S. Ferorelli, F. Loiodice, V. Tortorella, D. Conte-Camerino, and A. De Luca Farmaco 56 2001 239 246
19. G. Carbonara, G. Fracchiolla, F. Loiodice, P. Tortorella, D. Conte-Camerino, A. De Luca, and A. Liantonio Farmaco 56 2001 749 754
20. A. Liantonio, A. Accardi, G. Carbonara, G. Fracchiolla, F. Loiodice, P. Tortorella, S. Traverso, P. Guida, S. Pierno, A. De Luca, D. Conte-Camerino, and M. Push Mol. Pharmacol. 62 2002 265 272
21. 7a-f were prepared modifying (Sheme in Table 1) the procedure reported by C. Trebaul, J. Teste, Bull. Soc. Chim. 7 (1969) 2456-2462 (the modified procedure requires shorter reaction time, 1-3:h instead of one night. If the reaction mixture was left (under stirring or not) for more than 3:h others mono- and di-halogenated compounds were the main reaction products).
22. P. Cronet, J.F.W. Petersen, R. Folmer, R. Blomberg, K. Sjoblom, U. Karlsson, E.-L. Lindstedt, and K. Bamberg Structure 9 2001 699 706
23. P. Sauemberg, I. Pettersson, L. Jeppensen, P.S. Bury, J.P. Mogensen, K. Wassermann, C.L. Brand, J. Sturis, H.F. Woldike, J. Fleckner, A.-S.T. Andersen, S.B. Mortensen, L.A. Svensson, H.B. Rasmussen, S.V. Lehmann, Z. Polivka, K. Sindelar, V. Panajotova, L. Ynddal, and E.M. Wulff J. Med. Chem. 45 2002 789 804
24. Ethyl 2-(4-chlorophenoxy)-3-oxobutanoate (8a) was prepared by using different conditions in a lower yield (48.8%) by J. Redondo, F. Sanchez-Ferrando, M. Valls, A. Virgili, Magn. Reson. 26 (1988) 511-517.